U.S. Markets closed
  • S&P 500

    3,465.39
    +11.90 (+0.34%)
     
  • Dow 30

    28,335.57
    -28.09 (-0.10%)
     
  • Nasdaq

    11,548.28
    +42.28 (+0.37%)
     
  • Russell 2000

    1,640.50
    +10.25 (+0.63%)
     
  • Crude Oil

    39.78
    -0.86 (-2.12%)
     
  • Gold

    1,903.40
    -1.20 (-0.06%)
     
  • Silver

    24.70
    -0.01 (-0.04%)
     
  • EUR/USD

    1.1868
    +0.0042 (+0.3560%)
     
  • 10-Yr Bond

    0.8410
    -0.0070 (-0.83%)
     
  • Vix

    27.55
    -0.56 (-1.99%)
     
  • GBP/USD

    1.3038
    -0.0042 (-0.3207%)
     
  • USD/JPY

    104.7200
    -0.1200 (-0.1145%)
     
  • BTC-USD

    13,066.68
    +170.09 (+1.32%)
     
  • CMC Crypto 200

    260.05
    -1.40 (-0.54%)
     
  • FTSE 100

    5,860.28
    +74.63 (+1.29%)
     
  • Nikkei 225

    23,516.59
    +42.32 (+0.18%)
     

US STOCKS-S&P 500 ends lower as investors eye stimulus impasse

Noel Randewich
·3 mins read

(For a live blog on the U.S. stock market, click or type LIVE/ in a news window)

* Walgreens rises on 2021 profit growth forecast

* CBOE volatility index hits one-week high

* Weekly jobless claims unexpectedly rise in latest week (Updates to close)

By Noel Randewich

Oct 15 (Reuters) - The S&P 500 ended lower on Thursday after a rise in weekly jobless claims compounded worries about a stalling economic recovery and fading hopes for more fiscal aid before the election.

The number of Americans filing new claims for jobless benefits rose to a two-month high last week, stoking fears the COVID-19 pandemic was inflicting lasting damage to the labor market.

A separate report showed manufacturing activity in New York State fell more than expected in October.

"Going into the fall it will be difficult for unemployment to make a lot of positive headway because of the lack of stimulus," said Christopher C. Grisanti, chief equity strategist, MAI Capital Management in Cleveland.

U.S. President Donald Trump said he is willing to raise his offer of $1.8 trillion for a COVID-19 relief deal with Democrats in Congress, but the idea was shot down by his fellow Republican, Senate Majority Leader Mitch McConnell.

The CBOE volatility index, investors' fear gauge, hit a one-week high. The S&P 500 is down about 3% from its Sept. 2 record high close.

With less than 20 days until the Nov. 3 election, Trump and Democratic challenger Joe Biden are set to hold dueling prime-time town halls on Thursday instead of their second presidential debate, which was canceled after Trump declined to take part in a virtual matchup.

"More of what moves the market will be the crystallizing of who is going to win the presidency, and how close the Senate races are," said Tom Martin, senior portfolio manager at Globalt Investments in Atlanta.

A Biden presidency, coupled with a Democratic Senate, would likely mean a larger fiscal stimulus plan than what a Republicans Senate would agree to. However, Biden is also widely seen on Wall Street as likely to raise taxes.

Supporting the Dow Jones Industrial Average, Walgreens Boots Alliance Inc surged as the drugstore chain forecast single-digit profit growth in 2021 after reporting a better-than-expected fourth-quarter profit.

Focus is also on the quarterly results for corporate America, with expectations for third-quarter earnings improving to an 19% drop from a 25% tumble forecast on July 1, according to Refinitiv IBES data.

Unofficially, the Dow Jones Industrial Average fell 18.02 points, or 0.06%, to 28,495.98, the S&P 500 lost 5.32 points, or 0.15%, to 3,483.35 and the Nasdaq Composite dropped 54.86 points, or 0.47%, to 11,713.87.

Morgan Stanley rose after it beat third-quarter profit estimates, winding up mixed results from major U.S. lenders. Recent bank earnings reports saw those focused on trading clocking big gains, while retail banks took a hit from the COVID-19 pandemic.

The S&P 500 financials index climbed, while communication services was among the worst performers.

The S&P 1500 airlines index dipped after United Airlines reported a 78% drop in quarterly revenue.

Shares of Vertex Pharmaceuticals Inc lost close to a fifth of their value after the drug developer discontinued its trial of a protein deficiency disorder treatment. (Additional reporting by Medha Singh and Shivani Kumaresan in Bengaluru Editing by Nick Zieminski and Marguerita Choy)